Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients-Reference-Cited by-同舟云学术

Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients

Published:2020-01-20 Issue:1 Volume:180 Page:207-217
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Fayanju Oluwadamilola M.^ORCID,Ren Yi,Greenup Rachel A.,Plichta Jennifer K.,Rosenberger Laura H.,Force Jeremy,Suneja Gita,Devi Gayathri R.,King Tari A.,Nakhlis Faina,Hyslop Terry,Hwang E. Shelley

Funder

National Center for Advancing Translational Sciences

National Cancer Institute

National Institutes of Health

Office of Research on Women's Health

U.S. Department of Defense

IBC Network Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-020-05529-1.pdf

Reference27 articles.

1. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975

2. van Uden DJP, van Laarhoven HWM, Westenberg AH, de Wilt JHW, Blanken-Peeters CFJM (2015) Inflammatory breast cancer: an overview. Crit Rev Oncol/Hematol. 93(2):116–126

3. "Inflammatory Breast Cancer." NCCN Guideline Version 2.2019. https://www.nccn.org/. Accessed 2019 July 01.

4. Gianni L, Pienkowski T, Im Y-H et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791–800

5. Nahleh ZA, Barlow WE, Hayes DF et al (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158(3):485–495

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clipped Axillary Node as a Potential Surrogate for Overall Axillary Nodal Status in Inflammatory Breast Cancer Patients after Neoadjuvant Chemotherapy;Annals of Surgical Oncology;2024-08-09

2. Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities;Annals of Surgical Oncology;2024-07-21

3. Guideline-Concordant Surgical Care for Lobular Versus Ductal Inflammatory Breast Cancer;Annals of Surgical Oncology;2024-06-17

4. Axillary Surgery for Breast Cancer in 2024;Cancers;2024-04-23

5. Outcomes of Breast-Conserving Therapy in Patients With Inflammatory Breast Cancer: A Meta-Analysis;Journal of Surgical Research;2024-01